Is Iambic Therapeutics profitable?

No audited financials are public. Growjo estimates revenue around $19 to 20.3 million (low-confidence estimate), while the company has raised roughly $277-334M in venture funding through a Series C of over $100M closed November 10, 2025, suggesting it remains funded by investors rather than profits.

Who owns Iambic Therapeutics?

Iambic is a privately held, venture-backed company with no parent, as of July 2026. Investors include Lux Capital, NVIDIA, Ascenta Capital, Abingworth, Mubadala Capital, Qatar Investment Authority, Sequoia, and Regeneron Ventures, per its November 10, 2025 Series C announcement.

Could AI replace Iambic Therapeutics?

AI is Iambic's core product via its Enchant and NeuralPLexer models, but that same fact exposes its platform-licensing revenue to rivals like Alphabet-owned Isomorphic Labs, which shipped its IsoDDE engine in February 2026, reportedly doubling AlphaFold 3's protein-ligand performance.

Who is Iambic Therapeutics' biggest competitor?

Isomorphic Labs, Alphabet's AI drug discovery unit valued at roughly $15-20 billion as of June 2026, is the named frontier threat: it shipped IsoDDE in February 2026 and targets first human dosing of an AI-designed candidate by end of 2026, per Marketwise, June 29, 2026.

Does Iambic Therapeutics have real clinical data, not just AI hype?

Yes. At ESMO on October 20, 2025, Iambic presented Phase 1/1b data for lead candidate IAM1363 showing partial responses in 28% of patients (N=18) with measurable systemic disease and 33% (N=3) with measurable intracranial disease at doses of 960mg or higher once daily.

What major pharma partnerships does Iambic Therapeutics have?

Iambic has deals with Takeda (oncology and GI/inflammation), Lundbeck (migraine, announced September 26, 2024), Jazz Pharmaceuticals (IAM1363 plus zanidatamab combination, October 21, 2025), Revolution Medicines (data-for-platform access, 2025), and Bayer (small-molecule discovery, announced June 22, 2026).

AI companies and labs · United States

Iambic Therapeutics

iambic.ai ↗

AI-native biotech that designs small molecules and runs its own oncology trials.

Losing its protection

Assessed 21 July 2026 · Evidence as of 21 July 2026

The structural protection is eroding.

On the recordSince 21 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: IAM1363 Phase 1/1b dose-expansion and Jazz zanidatamab combo trial readouts

The call

Iambic has real clinical data and pharma deals, but its licensing business sits next to a much richer, faster-moving Isomorphic Labs.

Iambic Therapeutics uses artificial intelligence to discover and design new medicines, and it has already moved several drug candidates into human testing. The company is hard to copy because it has regulatory approval to test its AI-designed drugs in people and real clinical data, but a better-funded rival called Isomorphic Labs (owned by Google's parent company) just released a more advanced AI platform and is moving its own AI-designed drug into human trials by the end of 2026. The decisive question over the next few years is whether Iambic's experimental drugs work well enough in patient tests to prove its AI approach is genuinely valuable, or whether Isomorphic's superior technology and resources make Iambic's partnership deals with big pharma companies less attractive and less lucrative.

Why

AI pressure: Isomorphic Labs' IsoDDE platform. IsoDDE claims 2x AlphaFold3 accuracy and plans first human dosing of an AI-designed drug by end of 2026. Could AI do the core job? Only partly.

Bigger players: Alphabet, parent of Isomorphic Labs. Alphabet's balance sheet backs Isomorphic's deals with Eli Lilly, Novartis, and J&J, pulling big pharma partners away from smaller labs. Could a giant copy it? Probably.

What protects it. IND-cleared clinical pipeline with real human trial data gives Iambic proof Isomorphic still lacks.

What would change this call

Isomorphic Labs doses first AI-designed candidate in humans by end of 2026. Shows Isomorphic converting platform lead into clinical proof, pressuring Iambic's partnership pipeline.
Iambic announces or fails to announce a new pharma partnership of Bayer/Takeda scale in 2026. Tests whether Iambic can still win large licensing deals against Isomorphic.
IAM1363 Phase 1/1b dose-expansion and Jazz zanidatamab combo data readout. Determines if Iambic's clinical pipeline validates its moat independent of platform competition.

Key numbers

Series C raised over $100M (2025-11-10)
Series C-II add-on ~$27.77M (2026-04-07)
Post-money valuation ~$450-550M (2026-04-07)

Named risks

Isomorphic Labs (Alphabet-backed) could commoditize Iambic's platform-licensing revenue with superior shipped tools. Severity: high
Equity outcome hinges on binary Phase 2 readout for IAM1363, especially intracranial response durability. Severity: high
Revenue is concentrated in a handful of pharma partnership deals (Takeda, Lundbeck, Jazz, Bayer) rather than diversified income. Severity: medium
Private company with no audited public financials, limiting outside verification of revenue and burn rate. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Isomorphic Labs	gaining on	Shipped IsoDDE Feb 2026 claiming 2x AlphaFold3 performance; targets first human dosing by end of 2026
Insilico Medicine	contesting	Most advanced clinical AI-designed asset, IPF Phase 2a data published in Nature Medicine, May 2026
Recursion Pharmaceuticals	contesting	Public since Exscientia merger late 2024, ~$1.67-1.84B market cap as of June 29, 2026
Schrodinger	contesting	Public physics-based platform with ~$180-190M revenue as of March 4, 2026

Questions people ask

Is Iambic Therapeutics profitable?: No audited financials are public. Growjo estimates revenue around $19 to 20.3 million (low-confidence estimate), while the company has raised roughly $277-334M in venture funding through a Series C of over $100M closed November 10, 2025, suggesting it remains funded by investors rather than profits.
Who owns Iambic Therapeutics?: Iambic is a privately held, venture-backed company with no parent, as of July 2026. Investors include Lux Capital, NVIDIA, Ascenta Capital, Abingworth, Mubadala Capital, Qatar Investment Authority, Sequoia, and Regeneron Ventures, per its November 10, 2025 Series C announcement.
Could AI replace Iambic Therapeutics?: AI is Iambic's core product via its Enchant and NeuralPLexer models, but that same fact exposes its platform-licensing revenue to rivals like Alphabet-owned Isomorphic Labs, which shipped its IsoDDE engine in February 2026, reportedly doubling AlphaFold 3's protein-ligand performance.
Who is Iambic Therapeutics' biggest competitor?: Isomorphic Labs, Alphabet's AI drug discovery unit valued at roughly $15-20 billion as of June 2026, is the named frontier threat: it shipped IsoDDE in February 2026 and targets first human dosing of an AI-designed candidate by end of 2026, per Marketwise, June 29, 2026.
Does Iambic Therapeutics have real clinical data, not just AI hype?: Yes. At ESMO on October 20, 2025, Iambic presented Phase 1/1b data for lead candidate IAM1363 showing partial responses in 28% of patients (N=18) with measurable systemic disease and 33% (N=3) with measurable intracranial disease at doses of 960mg or higher once daily.
What major pharma partnerships does Iambic Therapeutics have?: Iambic has deals with Takeda (oncology and GI/inflammation), Lundbeck (migraine, announced September 26, 2024), Jazz Pharmaceuticals (IAM1363 plus zanidatamab combination, October 21, 2025), Revolution Medicines (data-for-platform access, 2025), and Bayer (small-molecule discovery, announced June 22, 2026).

Timeline

2026-06-22Announced Bayer collaboration for AI-driven small-molecule discovery using Enchant and NeuralPLexer
2026-04-08Series C-II add-on tranche of roughly $27.77M per CB Insights
2025-11-10Closed Series C financing of over $100M with sovereign wealth and life-science investors
2025-10-21Signed Jazz Pharmaceuticals collaboration combining IAM1363 with zanidatamab in HER2+ breast cancer
2025-10-20Presented IAM1363 Phase 1/1b data at ESMO showing systemic and intracranial responses
2024-09-26Announced strategic research collaboration with Lundbeck for migraine drug discovery
2024-06-18Closed $50M Series B extension from Mubadala Capital, Exor Ventures, and QIA
2024-02-07Opened new 12,000+ sq ft San Diego HQ in Sorrento Valley
2023-10-03Closed $100M Series B co-led by Ascenta Capital and Abingworth, with NVIDIA joining as investor

Revision history

21 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Safe Superintelligence Inc.Mistral AI Cohere